Literature DB >> 28775638

SILDENAFIL-ORAL MEDICATION FOR ERECTILE DYSFUNCTION-A REVIEW.

N Srinath1, S V Kotwal2.   

Abstract

Problem of male erectile dysfunction has been better defined, recognised and being treated in the recent times. However, the intracavernosal injection of vaso-active materials and penile prosthesis implantation were only the viable options available. Sildenafil, which is a specific phosphodiesterase type V inhibitor, enhances erection on sexual arousal by increasing the quantity of cyclic guanosine monophosphate in the corpora cavernosa. This has revolutionized the treatment of erectile dysfunction. Though the drug appears very promising with little side effects, many questions regarding efficacy, safety, misuse and overuse need to be addressed.

Entities:  

Keywords:  Erectile dysfunction; Sildenafil

Year:  2017        PMID: 28775638      PMCID: PMC5531881          DOI: 10.1016/S0377-1237(17)30452-5

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  9 in total

1.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group.

Authors:  I Goldstein; T F Lue; H Padma-Nathan; R C Rosen; W D Steers; P A Wicker
Journal:  N Engl J Med       Date:  1998-05-14       Impact factor: 91.245

2.  The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.

Authors:  R C Rosen; A Riley; G Wagner; I H Osterloh; J Kirkpatrick; A Mishra
Journal:  Urology       Date:  1997-06       Impact factor: 2.649

Review 3.  Role of nitric oxide in the physiology of erection.

Authors:  A L Burnett
Journal:  Biol Reprod       Date:  1995-03       Impact factor: 4.285

Review 4.  Physiology of penile erection.

Authors:  K E Andersson; G Wagner
Journal:  Physiol Rev       Date:  1995-01       Impact factor: 37.312

5.  Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group.

Authors:  H Padma-Nathan; W J Hellstrom; F E Kaiser; R F Labasky; T F Lue; W E Nolten; P C Norwood; C A Peterson; R Shabsigh; P Y Tam; V A Place; N Gesundheit
Journal:  N Engl J Med       Date:  1997-01-02       Impact factor: 91.245

6.  Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. The American Urological Association.

Authors:  D K Montague; J H Barada; A M Belker; L A Levine; P W Nadig; C G Roehrborn; I D Sharlip; A H Bennett
Journal:  J Urol       Date:  1996-12       Impact factor: 7.450

7.  Sildenafil, a novel effective oral therapy for male erectile dysfunction.

Authors:  M Boolell; S Gepi-Attee; J C Gingell; M J Allen
Journal:  Br J Urol       Date:  1996-08

8.  Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.

Authors:  M Boolell; M J Allen; S A Ballard; S Gepi-Attee; G J Muirhead; A M Naylor; I H Osterloh; C Gingell
Journal:  Int J Impot Res       Date:  1996-06       Impact factor: 2.896

9.  Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group.

Authors:  O I Linet; F G Ogrinc
Journal:  N Engl J Med       Date:  1996-04-04       Impact factor: 91.245

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.